{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:07:42Z","timestamp":1793444862737,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and ischemic strokes. New data concerning TZD-mediated edema, congestive heart failure, and bone fractures improves the clinician\u2019s ability to select patients that will have minimal significant side effects.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Thiazolidinediones are now generic and less costly than pharmaceutical company\u2013promoted therapies. Better understanding of the side effects coupled with clear benefits on the components of the insulin resistance syndrome should promote TZD use in treating patients with type 2 diabetes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11892-019-1270-y","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T21:02:28Z","timestamp":1574888548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":351,"title":["Thiazolidinediones: the Forgotten Diabetes Medications"],"prefix":"10.1007","volume":"19","author":[{"given":"Harold E.","family":"Lebovitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,27]]},"reference":[{"key":"1270_CR1","doi-asserted-by":"crossref","unstructured":"\u2022 Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. 1999;104:787\u201394. This is the classic study that documents the relationship between insulin resistance and insulin secretion.","DOI":"10.1172\/JCI7231"},{"key":"1270_CR2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1152\/physrev.00024.2006","volume":"87","author":"DB Savage","year":"2007","unstructured":"\u2022\u2022 Savage DB, Petersen KF, Shulman GI. Disordered Lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev. 2007;87:507\u201320. This review outlines how ectopic fat leads to insulin resistance.","journal-title":"Physiol Rev"},{"key":"1270_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2004.02.051","volume":"490","author":"HE Lebovitz","year":"2004","unstructured":"\u2022\u2022 Lebovitz HE, Banerji MA. Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol. 2004;490:135\u201346. This summarizes the beneficial effects of TZDs on the insulin resistance syndrome.","journal-title":"Eur J Pharmacol"},{"key":"1270_CR4","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nm.4350","volume":"7","author":"MP Czech","year":"2017","unstructured":"Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;7:804\u201314.","journal-title":"Nat Med"},{"key":"1270_CR5","volume-title":"The metabolic syndrome chapter 13.36 in Oxford textbook of endocrinology and diabetes 2nd Edition","author":"HE Lebovitz","year":"2011","unstructured":"Lebovitz HE. In: Wass JAH, Stewart PM, editors. The metabolic syndrome chapter 13.36 in Oxford textbook of endocrinology and diabetes 2nd Edition. Oxford: OXFORD University Press; 2011."},{"key":"1270_CR6","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","volume":"37","author":"GM Reaven","year":"1988","unstructured":"\u2022 Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595\u2013607. This summarizes the pioneer studies which formulated the concept of insulin resistance as a cause of atherosclerotic disease.","journal-title":"Diabetes"},{"key":"1270_CR7","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1210\/jc.2006-0594","volume":"91","author":"JB Meigs","year":"2006","unstructured":"Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906\u201312.","journal-title":"J Clin Endocrinol Metab"},{"key":"1270_CR8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","volume":"28","author":"ES Ford","year":"2005","unstructured":"Ford ES. Risks for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome. Diabetes Care. 2005;28:1769\u201378.","journal-title":"Diabetes Care"},{"key":"1270_CR9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diab.38.6.784","volume":"38","author":"MA Banerji","year":"1989","unstructured":"Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38:784\u201392.","journal-title":"Diabetes."},{"key":"1270_CR10","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2337\/diabetes.52.5.1210","volume":"52","author":"CM Alexander","year":"2003","unstructured":"\u2022\u2022 Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210\u20134. This study helps to define diabetes mellitus and the metabolic syndrome as separate but interacting metabolic abnormalities.","journal-title":"Diabetes"},{"key":"1270_CR11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","volume":"367","author":"Origin Trial Investigators","year":"2012","unstructured":"Origin Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319\u201328.","journal-title":"N Engl J Med"},{"key":"1270_CR12","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, El Aziz MA, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849\u201370.","journal-title":"Circulation"},{"key":"1270_CR13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi E, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonist in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524\u201336.","journal-title":"Diabetes Obes Metab"},{"key":"1270_CR14","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/1440-1681.12455","volume":"42","author":"HZ-X ChenX-W","year":"2015","unstructured":"ChenX-W HZ-X, Zhou Z-W, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015;42:999\u20131024.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"1270_CR15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","volume":"124","author":"A Merovci","year":"2014","unstructured":"Merovci A, Solis-Herrera C, Daniele G, Eldor R, Florentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509\u201314.","journal-title":"J Clin Invest"},{"key":"1270_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","volume":"124","author":"E Ferrannini","year":"2014","unstructured":"Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499\u2013508.","journal-title":"J Clin Invest"},{"key":"1270_CR17","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","volume":"54","author":"EL Lim","year":"2011","unstructured":"\u2022 Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalization of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54:2506\u201314. One of the best demonstrations of the effect of weight loss on metabolic processes.","journal-title":"Diabetologia"},{"key":"1270_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1210\/rp.56.1.265","volume":"56","author":"HE Lebovitz","year":"2001","unstructured":"\u2022\u2022 Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265\u201394. A summary of the beneficial effects of TZDs on the components of the insulin resistance syndrome.","journal-title":"Recent Prog Horm Res"},{"key":"1270_CR19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","volume":"77","author":"P Tontonoz","year":"2008","unstructured":"Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPAR\u03b3. Annu Rev Biochem. 2008;77:289\u2013312.","journal-title":"Annu Rev Biochem"},{"key":"1270_CR20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1043-2760(00)00306-4","volume":"11","author":"JM Olefsky","year":"2000","unstructured":"Olefsky JM, Saltiel AR. PPAR\u03b3 and the treatment of insulin resistance. Trends in Endocrinol and Metab. 2000;11:362\u20138.","journal-title":"Trends in Endocrinol and Metab"},{"key":"1270_CR21","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","volume":"333","author":"M Stumvoll","year":"1995","unstructured":"Stumvoll M, Nurjahan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550\u20134.","journal-title":"N Engl J Med"},{"key":"1270_CR22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"I Pernicova","year":"2014","unstructured":"Pernicova I, Korbonits M. Metformin\u2014mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10:143\u201356.","journal-title":"Nat Rev Endocrinol"},{"key":"1270_CR23","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","volume":"116","author":"M Prentki","year":"2006","unstructured":"Prentki M, Nolan CJ. Islet \u03b2-cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802\u201312.","journal-title":"J Clin Invest"},{"key":"1270_CR24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"\u2022\u2022 Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371:1131\u201341. An excellent overview of the relationship between ectopic fat and its mechanism in creating insulin resistance and cardiovascular disease.","journal-title":"N Engl J Med"},{"key":"1270_CR25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","volume":"72","author":"JM Olefsky","year":"2010","unstructured":"Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219\u201346.","journal-title":"Annu Rev Physiol"},{"key":"1270_CR26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000212758","volume":"55","author":"M Zeyda","year":"2009","unstructured":"Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance\u2014a mini-review. Gerontology. 2009;55:379\u201386.","journal-title":"Gerontology"},{"key":"1270_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","volume":"17","author":"R Kaur","year":"2018","unstructured":"Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol. 2018;17:121.","journal-title":"Cardiovasc Diabetol"},{"key":"1270_CR28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1172\/JCI29189","volume":"116","author":"M Kasuga","year":"2006","unstructured":"Kasuga M. Insulin resistance and \u03b2 cell failure. J Clin Invest. 2006;116:1756\u201360.","journal-title":"J Clin Invest"},{"key":"1270_CR29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00125-017-4504-z","volume":"61","author":"R Taylor","year":"2018","unstructured":"Taylor R, Barnes AC. Translating aetiological insight into sustainable management of type 2 diabetes. Diabetologia. 2018;61:273\u201383.","journal-title":"Diabetologia"},{"key":"1270_CR30","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.2337\/diabetes.54.8.2460","volume":"54","author":"B Staels","year":"2005","unstructured":"Staels B, Fruchart J-C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005;54:2460\u201370.","journal-title":"Diabetes"},{"key":"1270_CR31","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","volume":"368","author":"The DREAM Trial Investigators","year":"2006","unstructured":"\u2022 The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096\u2013105. TZDs decrease insulin resistance and preserve beta-cell function.","journal-title":"Lancet"},{"key":"1270_CR32","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, Banerji MA, Bray GA, Buchanan TA, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104\u201315.","journal-title":"N Engl J Med"},{"key":"1270_CR33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","volume":"3","author":"P Gervois","year":"2007","unstructured":"Gervois P, Fruchard J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonist of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol and metab. 2007;3:145\u201356.","journal-title":"Nat Clin Pract Endocrinol and metab"},{"key":"1270_CR34","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427\u201343.","journal-title":"N Engl J Med"},{"key":"1270_CR35","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","volume":"108","author":"RW Nesto","year":"2003","unstructured":"\u2022 Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941\u20138. Focused attention on TZD effects in increasing fluid retention and precipitating heart failure.","journal-title":"Circulation"},{"key":"1270_CR36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","volume":"31","author":"SE Kahn","year":"2008","unstructured":"\u2022\u2022 Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes. An Analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31:845\u201351. First recognition that TZDs cause an increased risk of peripheral skeletal fractures.","journal-title":"Diabetes Care"},{"key":"1270_CR37","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"1270_CR38","first-page":"1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A Meta-analysis JAMA. 2007;298:1189\u201395.","journal-title":"A Meta-analysis JAMA"},{"key":"1270_CR39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00125-012-2538-9","volume":"55","author":"A Neumann","year":"2012","unstructured":"Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953\u201362.","journal-title":"Diabetologia"},{"key":"1270_CR40","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"\u2022\u2022 Dormandy JA, Charbonnel B, DJA E, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention on macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized, controlled trial. Lancet. 2005;366:1279\u201389. Initial cardiovascular safety trial for a single antidiabetic drug. Data suggest a possible benefit of TZDs in reducing cardiovascular events in patients with type 2 diabetes.","journal-title":"Lancet"},{"key":"1270_CR41","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","volume":"374","author":"WN Kernan","year":"2016","unstructured":"\u2022\u2022 Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. New Engl J Med. 2016;374:1321\u201331. This study proves the beneficial effects of pioglitazone in reducing CV events in patients with type 2 diabetes.","journal-title":"New Engl J Med"},{"key":"1270_CR42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","volume":"5","author":"O Vaccaro","year":"2017","unstructured":"Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggoini AP, et al. Effects of the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol. 2017;5:887\u201397.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1270_CR43","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","volume":"373","author":"RD Home","year":"2009","unstructured":"\u2022\u2022 Home RD, Pocock S, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicenter, randomized, open label trial. Lancet. 2009;373:2125\u201335. A mediocre CV safety study with rosiglitazone. It did however dispel the claims that rosiglitazone caused an increase in CV events and death in patients with type 2 diabetes.","journal-title":"Lancet"},{"key":"1270_CR44","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","volume":"38","author":"R Wilcox","year":"2007","unstructured":"Wilcox R, Bousser M_G, Betteridge J, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865\u201373.","journal-title":"Stroke"},{"key":"1270_CR45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaneurol.2017.2136","volume":"74","author":"WN Kernan","year":"2017","unstructured":"Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit CR, Fayad P, et al. Targeting pioglitazone hydrochloride therapy after stroke or transient ischemic attack according to pretreatment risk for stroke or myocardial infarction. JAMA Neurol. 2017;74:1319\u201327.","journal-title":"JAMA Neurol"},{"key":"1270_CR46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/STROKEAHA.116.013977","volume":"48","author":"M Lee","year":"2017","unstructured":"Lee M, Saver JL, Liao H-W, Lin C-H, Ovbiagele B. Pioglitazone for secondary stroke prevention: a systemic review and meta-analysis. Stroke. 2017;48:388\u201393.","journal-title":"Stroke"},{"key":"1270_CR47","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","volume":"299","author":"SE Nissen","year":"2008","unstructured":"Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glomepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. JAMA. 2008;299:1561\u201373.","journal-title":"JAMA"},{"key":"1270_CR48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc08-9016","volume":"31","author":"DM Nathan","year":"2008","unstructured":"Nathan DM, Buse JB, Dasvidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2008;31:173\u20135.","journal-title":"Diabetes Care"},{"key":"1270_CR49","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.jacc.2010.02.014","volume":"55","author":"S Kaul","year":"2010","unstructured":"Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks. J Amer Coll Cardiol. 2010;55:1885\u201394.","journal-title":"J Amer Coll Cardiol"},{"key":"1270_CR50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2010.954","volume":"304","author":"DN Juurlink","year":"2010","unstructured":"Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA. 2010;304:469\u201371.","journal-title":"JAMA"},{"key":"1270_CR51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMp1008233","volume":"363","author":"CJ Rosen","year":"2010","unstructured":"\u2022 Rosen CJ. Revisiting the rosiglitazone story\u2013lessons learned. N Engl J Med. 2010;363:803\u20136. Reviews the FDA deliberations which lead to the FDA restricting the use of rosiglitazone.","journal-title":"N Engl J Med"},{"key":"1270_CR52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1345\/aph.1Q400","volume":"46","author":"CA Bourg","year":"2012","unstructured":"Bourg CA, Phillips BB. Rosiglitazone, myocardial ischemic risk and recent regulatory actions. Ann Pharmacother. 2012;46:282\u20139.","journal-title":"Ann Pharmacother"},{"key":"1270_CR53","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","volume":"304","author":"DJ Graham","year":"2010","unstructured":"Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411\u20138.","journal-title":"JAMA"},{"key":"1270_CR54","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jama.2013.8141","volume":"310","author":"M Mitka","year":"2013","unstructured":"Mitka M. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA. 2013;310:246\u20137.","journal-title":"JAMA"},{"key":"1270_CR55","unstructured":"FDA Drug Safety Communication. FDA requires removal of some prescribing and dispensing restrictions for rosiglitazone-containing diabetes medicines. Nov. 2013;25."},{"key":"1270_CR56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00125-011-2357-4","volume":"55","author":"The Tide Trial Investigators","year":"2012","unstructured":"The Tide Trial Investigators. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomized controlled trial. Diabetologia. 2012;55:36\u201345.","journal-title":"Diabetologia"},{"key":"1270_CR57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/CIRCULATIONAHA.112.000678","volume":"128","author":"RG Bach","year":"2013","unstructured":"Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A, et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary heart disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013;128:785\u201394.","journal-title":"Circulation"},{"key":"1270_CR58","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/dom.12487","volume":"17","author":"H Florez","year":"2015","unstructured":"Florez H, Reaven PD, Bahn G, Moritz T, Warren S, Marks J, et al. Rosiglitazone treatment and cardiovascular disease in Veterans Affairs Diabetes Trial. Diabetes Obes Metab. 2015;17:949\u201355.","journal-title":"Diabetes Obes Metab"},{"key":"1270_CR59","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.109.881003","volume":"121","author":"HC Gerstein","year":"2010","unstructured":"Gerstein HC, Ratner RE, Cannon CP, Serruys PW, Garcia-Garcia HM, van Eas G-A, et al. Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease. The assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes with cardiovascular history trial. Circulation. 2010;121:1176\u201387.","journal-title":"Circulation"},{"key":"1270_CR60","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.2337\/diacare.27.11.2654","volume":"27","author":"D Choi","year":"2004","unstructured":"Choi D, Kim S-K, Choi S-H, Ko Y-G, Ahn C-W, Jang Y, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654\u201360.","journal-title":"Diabetes Care"},{"key":"1270_CR61","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jacc.2006.10.077","volume":"49","author":"HJ Dargie","year":"2007","unstructured":"Dargie HJ, Hildebrandt PR, Piegger GAJ, McMurray JJV, McMorn SO, Roberts JN, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 patients with New York heart association functional class I or II heart failure. J Am Coll Cardiol. 2007;49:1696\u2013704.","journal-title":"J Am Coll Cardiol"},{"key":"1270_CR62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000370254","volume":"129","author":"Y Fu","year":"2015","unstructured":"Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, et al. PPAR\u03b3 agonist-induced fluid retention depends on \u03b1ENaC expression in connecting tubules. Nephron. 2015;129:68\u201374.","journal-title":"Nephron"},{"key":"1270_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/646423","volume":"2015","author":"Shoko Horita","year":"2015","unstructured":"Horita S, Nakamura M, Satoh N, Suzuki M, Seki G. Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Research. 2015. https:\/\/doi.org\/10.1155\/2015\/646423.","journal-title":"PPAR Research"},{"key":"1270_CR64","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","volume":"30","author":"E Erdmann","year":"2007","unstructured":"\u2022\u2022 Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease. Data from the PROactive Study (PROactive 08). Diabetes Care. 2007;30:2773\u20138. Detailed analysis fluid retention and heart failure development and outcome with pioglitazone treatment.","journal-title":"Diabetes Care"},{"key":"1270_CR65","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1161\/CIRCULATIONAHA.118.034763","volume":"138","author":"LH Young","year":"2018","unstructured":"Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, et al. Heart failure after ischemic stroke or transient ischemic attack in insulin-resistant patients without diabetes mellitus treated with pioglitazone. Circulation. 2018;138:1210\u201320.","journal-title":"Circulation"},{"key":"1270_CR66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-11-5","volume":"11","author":"S Berthet","year":"2011","unstructured":"\u2022 Berthet S, Oliver P, Montastruc J-L, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. BMC Clin Pharmacol. 2011;11:5. This study lead to the restriction of pioglitazone use in France and Germany.","journal-title":"BMC Clin Pharmacol"},{"key":"1270_CR67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.pharmthera.2016.09.007","volume":"168","author":"Ilia Goltsman","year":"2016","unstructured":"Goltsman I, Khoury EE, Winaver J, Abassi Z. Does thiazolidinedione therapy exacerbate fluid retention in congestive heart failure? Pharmacol Ther. 2016:75\u201397.","journal-title":"Pharmacology & Therapeutics"},{"key":"1270_CR68","first-page":"166","volume":"22","author":"E Wooltorton","year":"2002","unstructured":"Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ. 2002;22:166.","journal-title":"CMAJ"},{"key":"1270_CR69","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","volume":"26","author":"TE Delea","year":"2003","unstructured":"Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2003;26:2983\u20139.","journal-title":"Diabetes Care"},{"issue":"1","key":"1270_CR70","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacc.2007.04.026","volume":"50","author":"Carl V. Leier","year":"2007","unstructured":"Leier CV, Haas GJ. Diabetes and heart failure. J Ame Coll Cardiol. 2007; 50:","journal-title":"Journal of the American College of Cardiology"},{"key":"1270_CR71","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(07)61514-1","volume":"370","author":"RM Lago","year":"2007","unstructured":"Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet. 2007;370:1129\u201336.","journal-title":"Lancet"},{"key":"1270_CR72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2007.01.096","volume":"50","author":"D Aguilar","year":"2007","unstructured":"\u2022\u2022 Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Amer Coll Cardiol. 2007;50:32\u20136. Best data on the effect of TZD treatment in patients with heart failure.","journal-title":"J Amer Coll Cardiol"},{"key":"1270_CR73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-200932030-00002","volume":"32","author":"J Dormandy","year":"2009","unstructured":"Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32:187\u2013202.","journal-title":"Drug Saf"},{"key":"1270_CR74","first-page":"914","volume":"102","author":"CM Viscoli","year":"2017","unstructured":"\u2022 Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, et al. Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab. 2017;102:914\u201322. Adds additional information about TZD effects on bone fracture. Significant relationship to falls and does occur in high-risk men.","journal-title":"J Clin Endocrinol Metab"},{"key":"1270_CR75","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/jc.2015-1215","volume":"100","author":"AV Schwartz","year":"2015","unstructured":"\u2022 Schwartz AV, Chen H, Ambrosius WT, Soad A, Josse RG, Bonds DE, et al. Effects of TZD use and discontinuation on fracture rates in ACCORD bone study. J Clin Endocrinol Metab. 2015;100:4059\u201366. An excellent analysis of TZD fracture risk in women and its requirement for continuing exposure.","journal-title":"J Clin Endocrinol Metab"},{"key":"1270_CR76","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","volume":"314","author":"JD Lewis","year":"2015","unstructured":"\u2022\u2022 Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265\u201377. The data indicate that pioglitazone does not increase bladder cancer in men.","journal-title":"JAMA"},{"key":"1270_CR77","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jdiacomp.2016.04.004","volume":"30","author":"MB Davidson","year":"2016","unstructured":"Davidson MB. Pioglitazone (Actos) and bladder cancer: legal system triumphs over the evidence. J Diabetes Complicat. 2016;30:981\u20135.","journal-title":"J Diabetes Complicat"},{"key":"1270_CR78","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s13300-017-0273-4","volume":"8","author":"E Filipova","year":"2017","unstructured":"Filipova E, Uzunova K, Kalinov K, Vekov T. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017;8:706\u201326.","journal-title":"Diabetes Ther"},{"key":"1270_CR79","first-page":"i5141","volume":"352","author":"M Tuccori","year":"2016","unstructured":"Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population-based cohort study. BMJ. 2016;352:i5141.","journal-title":"BMJ"},{"key":"1270_CR80","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1021\/jm950395a","volume":"39","author":"TM Willison","year":"1996","unstructured":"Willison TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, et al. The structure-activity relationship between peroxisome proliferator-activated receptor \u03b3 agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39:665\u20138.","journal-title":"J Med Chem"},{"key":"1270_CR81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","volume":"3","author":"P Gervois","year":"2007","unstructured":"Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145\u201355.","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"1270_CR82","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","volume":"278","author":"J Sakamoto","year":"2000","unstructured":"Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophy Res Commun. 2000;278:704\u201311.","journal-title":"Biochem Biophy Res Commun"},{"key":"1270_CR83","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.1021\/jm301204r","volume":"55","author":"BR Hoffmann","year":"2012","unstructured":"Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012;55:8260\u201371.","journal-title":"J Med Chem"},{"issue":"10","key":"1270_CR84","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.2337\/dc06-1903","volume":"30","author":"D Ma","year":"2007","unstructured":"Ma D, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458\u201364 Epub 2007 Jun 26.","journal-title":"Diabetes Care"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-019-1270-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-019-1270-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T01:23:58Z","timestamp":1606353838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-019-1270-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1270"],"URL":"https:\/\/doi.org\/10.1007\/s11892-019-1270-y","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,27]]},"assertion":[{"value":"27 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Harold E. Lebovitz declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any new studies with human or animal subjects performed by any of the authors. All of the data quoted in this review have been published in peer-reviewed journals and would have complied with the standards of informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"151"}}